Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT
THE NDA OF SEMAGLUTIDE INJECTION DEVELOPED BY HUISHENG BIOPHARMACEUTICAL ACCEPTED BY THE NMPA

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "**Company**" or "**Sihuan Pharmaceutical**", together with its subsidiaries, the "**Group**") is pleased to announce that the new drug application ("**NDA**") of Semaglutide Injection developed by the Group's non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd ("**Huisheng Biopharmaceutical**") has been accepted by the National Medical Products Administration (the "**NMPA**") to improve glycemic control in adult patients with type 2 diabetes mellitus. Furthermore, Semaglutide Injection for weight loss indication has completed phase III clinical enrollment and is currently in the follow-up stage.

Semaglutide Injection is a long-acting GLP-1 receptor agonist (GLP-1 RA) injected once a week, which can enhance insulin secretion in a glucose concentration dependent manner by activating GLP-1 receptors, inhibit glucagon secretion, and delay gastric emptying, thereby achieving the effect of lowering blood glucose; At the same time, Semaglutide can reduce appetite and food intake, helping patients reduce calorie intake and achieve weight loss.

According to the latest data of the International Diabetes Federation (IDF), the number of diabetes patients in China was 148 million in 2024 (accounting for 25.1% of the world), and is expected to grow to 168.3 million by 2050. According to Novo Nordisk financial report data, in the first half of 2025, the sales of Semaglutide Injection of Novo Nordisk for diabetes was about DKK64.5 billion (equivalent to US$10.1 billion, based on DKK1≈ US$0.1562, the same below), with a year-on-year increase of 15%; the sales of Semaglutide Injection for weight loss was about DKK36.9 billion (equivalent to US$5.8 billion), a year-on-year increase of 78%.

Diabetes is the key deployment area of Huisheng Biopharmaceutical. The NDA of Semaglutide Injection was accepted by the NMPA, which is another major milestone in its R&D process, helping to further enhance the core competitiveness of both the Group and Huisheng Biopharmaceutical in the field of diabetes treatment.

ABOUT HUISHENG BIOPHARMACEUTICAL

Huisheng Biopharmaceutical is a biopharmaceutical company under Sihuan Pharmaceutical, a large domestic medical aesthetics and pharmaceutical group, focusing on the areas of diabetes and complications. After ten years of construction and development, Huisheng Biopharmaceutical has become one of the few companies in China that has achieved full product coverage in the field of diabetes and related complications, and integrated the whole industrial chain of R&D, production and sales. The company's product pipeline covers more than 20 products of diabetes and complication drugs, such as SGLT-2 receptor inhibitor class 1 innovative drug Proline Ganagliflozin Tablets, all types of insulin represented by Insulin Degludec and Insulin Aspart Injection (IDegAsp) and Insulin Degludec Injection (including long-, fast-, and premixed insulin), and GLP-1 receptor agonist Semaglutide Injection, etc. Huisheng Biopharmaceutical is committed to providing full-process, all-round integrated treatment solutions for diabetic patients, serving patients and making health easier.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 15 August 2025

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.